在我们的博客for Clinical Trials Day 2020 we summarized the COVID-19 studies that had been registered so far at theISRCTN注册表。一年后，现在已经结束了170COVID-19 studies registered. In this blog we look back at the results of the平台在我们的第一个博客中讨论的试验以及一系列的选择repurposed drug treatmenttrials that have launched since then.
平台试验
平台试验compare multiple treatments at the same time using a single protocol, allowing new treatments to be added and ineffective treatments to be dropped throughout the course of the trial.
世界卫生组织（WHO）组织国际SOLIDARITY试验并发现使用重新利用的抗病毒药物的治疗方案remdesivir，羟氯喹，洛皮内维尔和干扰素的治疗方案几乎没有效果on hospitalized patients.
RECOVERY
英国的RECOVERY试验是世界上最大的临床试验Covid-19的治疗方法，在撰写本文时，有177个试验地点的30,000多名参与者。它发现低成本类固醇地塞米松reduces mortality by up to one third among hospital patients receiving invasive mechanical ventilation or oxygen.
初步结果也表明tocilizumab(a treatment for rheumatoid arthritis) also改善生存和其他临床结果。However, the antiviralslopinavir–ritonavir和hydroxychloroquine, the antibiotic阿奇霉素和convalescent plasma没有降低死亡率。The antiviral antibody cocktail REGN-COV2 and the anti-inflammatory drugs aspirin and colchicine have since been added toRECOVERY。
原则
The原则试验是在老年人和英格兰GP实践中患有疾病的老年人和患有疾病的人的可疑Covid-19测试社区治疗。他们正在寻找治疗方法来帮助患有COVID-19症状的人迅速恢复，以便他们不需要去医院。
Hydroxychloroquine was originally included in the trial but was discontinued based on the results of the other studies. The antibiotics阿奇霉素和doxycyclinewere also found to be not generally effective。原则目前正在测试常用的吸入的皮质类固醇布地奈德和消炎（药）colchicine.
其他平台试验
其他平台试验includeACTT-EU/UK, which found thatremdesivirshortened the time to recovery in hospitalized adults.ACCORD-2is testing treatments including bemcentinib, MEDI-3506, acalabrutinib and zilucoplan.
我们目前对严重Covid-19的了解表明，免疫系统因感染而过度激活，这可能导致器官损害。
我们目前对严重Covid-19的了解表明，免疫系统因感染而过度激活，这可能导致器官损害。针对这些疾病的试验中的类风湿关节炎和无授权药物等自身免疫性疾病的患者许可的药物正在测试中，以查看它们是否可以防止这种免疫反应过度激活。
平台试验REMAP-CAPfound that immune modulation withtocilizumab and sarilumabimproved critically ill patients’ outcomes including survival, whileCATALYST正在比较包括单克隆抗体Gemtuzumab Ozogamicin，Namilumab和英夫利昔单抗的处理，以查看它们是否可以减少由病毒引起的体内炎症。
New trials
免疫调节
正在测试的其他单克隆抗体包括Adalimumab，正在研究AVID-CCtrial to see whether giving it to patients outside hospital can prevent progression to respiratory failure or death.
战术r还在早期招募患者开始表现出轻度的肺并发症，以查看再利用的药物Ravulizumab和Baricitib是否可以防止器官损害，并减少对ICU治疗和通风呼吸支持的需求。
Otilimab正在测试奥斯卡在后期患者的患者中，患有严重的肺并发症并需要氧气支持或机械通气的患者进行试验。
Antivirals
Several other antiviral drugs are in trials including favipiravir – theGETAFIX研究正在考虑将其提供给Covid-19症状的患者是否有助于症状，并减少康复所需的时间。
The离子研究正在测试抗病毒oseltamivir和新药物（IMU-838）的组合是否可以改善从COVID-19中恢复所需的时间。SNG001是一种含有抗病毒蛋白干扰素β的吸入药物，正在在SPRINTERtrial to see whether it can accelerate the recovery of hospitalized patients receiving oxygen.
其他重新利用的药物
试验中的其他药物包括醛固星, which is being tested to see if it can improve blood oxygen levels and reduce the need for oxygen therapy and other forms of breathing support. TheRECOVER试验正在调查降低血压的劳萨坦是否可以改善患者预后。
TheILIAD-7-UKtrial aims to find out whether the drug CYT107 can reduce mortality by reversing lymphopenia (where patients have abnormally low levels of white blood cells called lymphocytes) and T-cell exhaustion (which prevents the body from dealing with chronic viral infections).
带回家的消息
TheISRCTN注册表continues to support global research on COVID-19 by giving priority to prompt registration and reporting of COVID-19-related studies. All registered studies are made available worldwide through the WHO’s国际临床试验注册表平台(ICTRP), and all UK studies appear on成为研究的一部分。
在里面second part我们讨论的博客thevaccine试验和研究着眼于测试以及Covid-19对其他条件的影响。要了解有关BMC如何庆祝的更多信息Clinical Trials Day 2021，请访问我们专用页面。
评论